Length of stay after reaching clinical stability drives hospital costs associated with adult community-acquired pneumonia

Scandinavian Journal of Infectious Diseases

Volumn 45, Issue 3, 2013, Pages 219-226

  Cortoos, Pieter Jan ^a,b   Gilissen, Christa ^c   Laekeman, Gert ^a   Peetermans, Willy E ^d   Leenaers, Hilde ^c   Vandorpe, Luc ^c   Simoens, Steven ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c DEPARTMENT OF CARDIOLOGY   (Belgium)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Antibiotics; Belgium; Guidelines; Pneumonia; Quality indicator

Indexed keywords

ANTIBIOTIC AGENT; MOXIFLOXACIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BELGIUM; COMMUNITY ACQUIRED PNEUMONIA; DISEASE ASSOCIATION; FEMALE; HEALTH CARE QUALITY; HOSPITAL COST; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PNEUMONIA SEVERITY INDEX; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BELGIUM; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; FEMALE; HOSPITAL COSTS; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PNEUMONIA; STATISTICS, NONPARAMETRIC;

EID: 84874051338     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2012.726737     Document Type: Article

References (22)

1. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44(Suppl 2): S27-72.
2. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012; 67: 71-9.
3. Reyes S, Martinez R, Valles JM, Cases E, Menendez R. Determinants of hospital costs in community-acquired pneumonia. Eur Respir J 2008; 31: 1061-7.
4. Merchant S, Mullins CD, Shih YC. Factors associated with hospitalization costs for patients with community acquired pneumonia. Clin Ther 2003; 25: 593-610.
5. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-50.
6. Halm EA, Fine MJ, Kapoor WN, Singer DE, Marrie TJ, Siu AL. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med 2002; 162: 1278-84.
7. Drummond MF, Becker DL, Hux M, Chancellor JV, Duprat-Lomon I, Kubin R, et al. An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. Chest 2003; 124: 526-35.
8. Lloyd A, Holman A, Evers T. A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial. Curr Med Res Opin 2008; 24: 1279-84.
9. Schouten JA, Hulscher ME, Wollersheim H, Braspennning J, Kullberg BJ, van der Meer JW, et al. Quality of antibiotic use for lower respiratory tract infections at hospitals: (how) can we measure it? Clin Infect Dis 2005; 41: 450-60.
10. Schouten JA, Hulscher ME, Trap-Liefers J, Akkermans RP, Kullberg BJ, Grol RP, et al. Tailored interventions to improve antibiotic use for lower respiratory tract infections in hospitals: a cluster-randomized, controlled trial. Clin Infect Dis 2007; 44: 931-41.
11. Grömping U. Relative importance for linear regression in R: the package relaimpo. J Stat Softw 2006; 17: 1.
12. Bauer TT, Welte T, Ernen C, Schlosser BM, Thate-Waschke I, de Zeeuw J, et al. Cost analyses of community-acquired pneumonia from the hospital perspective. Chest 2005; 128: 2238-46.
13. Wong A, Elderkamp-de Groot R, Polder J, van Exel J. Predictors of long-term care utilization by Dutch hospital patients aged 65 +. BMC Health Serv Res 2010; 10: 110.
14. Paladino JA, Poretz D. Outpatient parenteral antimicrobial therapy today. Clin Infect Dis 2010; 51(Suppl 2): S198-208.
15. Ramanujam P, Rathlev NK. Blood cultures do not change management in hospitalized patients with community-acquired pneumonia. Acad Emerg Med 2006; 13: 740-5.
16. Ewig S, Schlochtermeier M, Goke N, Niederman MS. Applying sputum as a diagnostic tool in pneumonia: limited yield, minimal impact on treatment decisions. Chest 2002; 121: 1486-92.
17. Ewig S, Hecker H, Suttorp N, Marre R, Welte T; CAPNETZ study group. Moxifloxacin monotherapy versus ss-lactam mono-or combination therapy in hospitalized patients with community-acquired pneumonia. J Infect 2011; 62: 218-25.
18. Simoens S. Evidence for moxifloxacin in community-acquired pneumonia: the impact of pharmaco-economic considerations on guidelines. Curr Med Res Opin 2009; 25: 2447-57.
19. Ott SR, Hauptmeier BM, Ernen C, Lepper PM, Nuesch E, Pletz MW, et al. Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis. Eur Respir J 2012; 39: 611-8.
20. Martinez R, Reyes S, Lorenzo MJ, Menendez R. Impact of guidelines on outcome: the evidence. Semin Respir Crit Care Med 2009; 30: 172-8.
21. Kane RL, Bershadsky B, Weinert C, Huntington S, Riley W, Bershadsky J, et al. Estimating the patient care costs of teaching in a teaching hospital. Am J Med 2005; 118: 767-72.
22. Ewig S, Birkner N, Strauss R, Schaefer E, Pauletzki J, Bischoff H, et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 2009; 64: 1062-9.